Robbins Farley’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Robbins Farley’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3	Closed	-$210	–	173
2025 Q3	$210	Hold	3	–	–	﹤0.01%	166
2025 Q2	$193	Hold	3	–	–	﹤0.01%	163
2025 Q1	$191	Sell	3 -191	-98%	-$12.9K	﹤0.01%	146
2024 Q4	$12.9K	Sell	194 -95	-33%	-$6.55K	0.01%	106
2024 Q3	$20.2K	Buy	289 +1	+0.3%	+$69	0.01%	95
2024 Q2	$18.7K	Buy	288 +6	+2%	+$380	0.01%	95
2024 Q1	$18.3K	Sell	282 -12	-4%	-$781	0.01%	95
2023 Q4	$19.4K	Buy	294 +44	+18%	+$2.56K	0.01%	94
2023 Q3	$14.3K	Buy	250 +5	+2%	+$305	0.01%	106
2023 Q2	$15K	Sell	245 -22	-8%	-$1.37K	0.01%	99
2023 Q1	$16.8K	Buy	267 +4	+2%	+$258	0.01%	100
2022 Q4	$16.7K	Buy	263 +157	+148%	+$9.96K	0.01%	92
2022 Q3	$6K	Sell	106 -18	-15%	-$1.11K	﹤0.01%	101
2022 Q2	$7K	Buy	124 +17	+16%	+$979	0.01%	77
2022 Q1	$7K	Buy	107 +8	+8%	+$488	0.01%	96
2021 Q4	$7K	Buy	+99	New	+$7.17K	0.01%	101
2021 Q2	–	Sell	-95	Closed	-$7K	–	154
2021 Q1	$7K	Buy	95 +7	+8%	+$529	0.01%	120
2020 Q4	$6K	Buy	+88	New	+$5.57K	0.01%	93

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Robbins Farley's PBE Position: Q4 2025 in Review

Robbins Farley sold out of Invesco Biotechnology & Genome ETF (PBE) in Q4 2025, closing a stake of 3 shares — an estimated $210 sold.

Robbins Farley first reported a position in PBE in Q4 2020 and held it in 18 quarters. The position peaked at $20.2K in Q3 2024. 108 funds tracked by Wall St. Rank hold PBE as of Q4 2025.

Robbins Farley reported no remaining Invesco Biotechnology & Genome ETF position as of Q4 2025 after selling out during the quarter.
Robbins Farley sold 3 Invesco Biotechnology & Genome ETF shares in Q4 2025, an estimated $210.
Robbins Farley first reported a position in Invesco Biotechnology & Genome ETF in Q4 2020 and held it in 18 quarters.
Robbins Farley's Invesco Biotechnology & Genome ETF position peaked at $20.2K in Q3 2024.
108 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2025.

Based on Robbins Farley's 13F filing for Q4 2025, filed 23 Jan 2026.